Active Ingredient History
Oxaliplatin (brand name Eloxatin), a new generation of platinum derivatives discovered by Prof Kidani in 1976 at Nagoya University in Japan, was licensed-in and developed by Debiopharm. Eloxatin is typically administered in combination with fluorouracil and leucovorin for the adjuvant treatment of stage III colon cancer and for the treatment of advanced carcinoma of the colon or rectum. Oxaliplatin undergoes nonenzymatic conversion in physiologic solutions to active derivatives via displacement of the labile oxalate ligand. Several transient reactive species are formed, including monoaquo and diaquo 1,2-diaminocyclohexane (DACH) platinum, which covalently bind with macromolecules. Both inter- and intrastrand Pt-DNA crosslinks are formed. Crosslinks are formed between the N7 positions of two adjacent guanines (GG), adjacent adenine-guanines (AG), and guanines separated by an intervening nucleotide (GNG). These crosslinks inhibit DNA replication and transcription. Cytotoxicity is cell-cycle nonspecific. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Colonic Neoplasms (approved 2002)
Rectal Neoplasms (approved 2002)
Adenocarcinoma (Phase 3)
Adenoma (Phase 2)
Adenoma, Islet Cell (Phase 2/Phase 3)
Adrenocortical Carcinoma (Phase 2)
Anemia (Phase 1)
Angiogenesis Modulating Agents (Phase 2)
Antimetabolites (Phase 2)
Antineoplastic Agents (Phase 2)
Anus Neoplasms (Phase 2)
Appendiceal Neoplasms (Phase 1)
Appendix (Phase 2)
Ascorbic Acid (Phase 3)
Astrocytoma (Phase 2)
Bevacizumab (Phase 1/Phase 2)
Bile Duct Neoplasms (Phase 3)
Biliary Tract Neoplasms (Phase 3)
Brain Neoplasms (Phase 2)
BRCA1 Protein (Phase 1)
Breast Neoplasms (Phase 3)
Burkitt Lymphoma (Phase 2)
Capecitabine (Phase 2)
Carcinoid Tumor (Phase 2)
Carcinoma (Phase 3)
Carcinoma, Basal Cell (Phase 2)
Carcinoma, Hepatocellular (Phase 3)
Carcinoma, Islet Cell (Phase 2)
Carcinoma, Large Cell (Phase 2)
Carcinoma, Neuroendocrine (Phase 2)
Carcinoma, Non-Small-Cell Lung (Phase 3)
Carcinoma, Ovarian Epithelial (Phase 2)
Carcinoma, Pancreatic Ductal (Phase 2)
Carcinoma, Renal Cell (Phase 2)
Carcinoma, Squamous Cell (Phase 2)
Carcinoma, Transitional Cell (Phase 2)
Central Nervous System Neoplasms (Phase 2)
Cetuximab (Phase 2)
Chemoembolization, Therapeutic (Phase 2)
Chemoradiotherapy (Phase 3)
Chemotherapy, Adjuvant (Phase 3)
Cholangiocarcinoma (Phase 4)
Choriocarcinoma (Phase 1)
Circulating Tumor DNA (Phase 2)
Clonal Hematopoiesis (Phase 2)
Cognition Disorders (Phase 3)
Colonic Diseases (Phase 2)
Colonic Neoplasms (Phase 4)
Colorectal Neoplasms (Phase 4)
Cytokine-Induced Killer Cells (Phase 4)
Deficiency Diseases (Phase 2/Phase 3)
Diarrhea (Phase 1)
Digestive System Diseases (Phase 2)
Digestive System Neoplasms (Phase 2)
Disease-Free Survival (Phase 3)
Disease Progression (Phase 2)
DNA Repair-Deficiency Disorders (Phase 3)
Docetaxel (Phase 2/Phase 3)
Drug Evaluation (Phase 2)
Drugs, Investigational (Phase 2/Phase 3)
Drug Therapy (Phase 3)
Drug Therapy, Combination (Phase 2)
Endometrial Neoplasms (Phase 2)
Endostatins (Phase 2)
Ependymoma (Phase 2)
Esophageal Diseases (Phase 3)
Esophageal Neoplasms (Phase 4)
Esophageal Squamous Cell Carcinoma (Phase 3)
Esophagogastric Junction (Phase 3)
Fallopian Tube Neoplasms (Phase 3)
Fluorouracil (Phase 2/Phase 3)
Gallbladder Neoplasms (Phase 3)
Gastrectomy (Phase 2)
Gastrointestinal Diseases (Phase 2)
Gastrointestinal Neoplasms (Phase 3)
General Surgery (Phase 3)
Genes, erbB-2 (Phase 2)
Genital Neoplasms, Female (Phase 2/Phase 3)
Geriatrics (Phase 3)
Germinoma (Phase 1)
Glioblastoma (Phase 1/Phase 2)
Glioma (Phase 2)
Gliosarcoma (Phase 1/Phase 2)
Hamartoma (Phase 3)
Head and Neck Neoplasms (Phase 2)
Hepatoblastoma (Phase 3)
Hodgkin Disease (Phase 3)
Hospital Costs (Phase 3)
Immune System Diseases (Phase 2)
Immunotherapy (Phase 2)
Intestinal Diseases (Phase 2)
Intestinal Neoplasms (Phase 3)
Intraocular Lymphoma (Phase 1)
Irinotecan (Phase 2/Phase 3)
Kidney Diseases (Phase 1)
Klatskin Tumor (Phase 2)
Lapatinib (Phase 3)
Length of Stay (Phase 3)
Leukemia (Phase 1/Phase 2)
Leukemia, Hairy Cell (Phase 1)
Leukemia, Large Granular Lymphocytic (Phase 1)
Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)
Leukemia-Lymphoma, Adult T-Cell (Phase 2)
Leukemia, Myeloid, Acute (Phase 1/Phase 2)
Leukemia, Myeloid, Chronic-Phase (Phase 1)
Leukemia, Myelomonocytic, Chronic (Phase 1)
Liver Cirrhosis (Phase 3)
Liver Diseases (Phase 2)
Liver Neoplasms (Phase 4)
Liver Transplantation (Phase 3)
Lung Neoplasms (Phase 2/Phase 3)
Lymphoma (Phase 3)
Lymphoma, B-Cell (Phase 2)
Lymphoma, B-Cell, Marginal Zone (Phase 2)
Lymphoma, Extranodal NK-T-Cell (Phase 3)
Lymphoma, Follicular (Phase 2)
Lymphoma, Large B-Cell, Diffuse (Phase 3)
Lymphoma, Large-Cell, Anaplastic (Phase 1)
Lymphoma, Large-Cell, Immunoblastic (Phase 2/Phase 3)
Lymphoma, Mantle-Cell (Phase 2)
Lymphoma, Non-Hodgkin (Phase 3)
Lymphoma, T-Cell (Phase 3)
Lymphoma, T-Cell, Cutaneous (Phase 2)
Lymphoma, T-Cell, Peripheral (Phase 2)
Lymphomatoid Granulomatosis (Phase 1)
Medulloblastoma (Phase 2)
Melanoma (Phase 1/Phase 2)
Mesothelioma (Phase 2)
Microsatellite Instability (Phase 2/Phase 3)
Multiple Myeloma (Phase 1/Phase 2)
Mutation (Phase 3)
Myelodysplastic Syndromes (Phase 1/Phase 2)
Myeloproliferative Disorders (Phase 1)
Nasopharyngeal Carcinoma (Phase 2)
Nasopharyngeal Neoplasms (Phase 2)
Nausea (Phase 2)
Neoadjuvant Therapy (Phase 3)
Neoplasm Metastasis (Phase 4)
Neoplasm Recurrence, Local (Phase 3)
Neoplasms (Phase 4)
Neoplasms by Site (Phase 2)
Neoplasms, Germ Cell and Embryonal (Phase 2)
Neoplasms, Unknown Primary (Phase 2)
Neoplastic Syndromes, Hereditary (Phase 2/Phase 3)
Neuralgia (Phase 3)
Neuroblastoma (Phase 2)
Neuroectodermal Tumors (Phase 1)
Neuroendocrine Tumors (Phase 4)
Neutropenia (Phase 1)
Organ Preservation (Phase 1/Phase 2)
Oropharyngeal Neoplasms (Phase 2)
Osteosarcoma (Phase 2)
Ovarian Neoplasms (Phase 3)
Oxaliplatin (Phase 2/Phase 3)
Paclitaxel (Phase 2)
Pain (Phase 3)
Pancreas (Phase 1)
Pancreatic Neoplasms (Phase 3)
Pathology (Phase 3)
Peripheral Nerve Injuries (Phase 3)
Peripheral Nervous System Diseases (Phase 2/Phase 3)
Peritoneal Neoplasms (Phase 3)
Pharmacokinetics (Phase 2)
Polyneuropathies (Phase 3)
Postoperative Complications (Phase 4)
Primary Myelofibrosis (Phase 1)
Progression-Free Survival (Phase 2)
Prostatic Neoplasms (Phase 2/Phase 3)
Proto-Oncogene Proteins B-raf (Phase 2)
Quality of Life (Phase 3)
Radiation (Phase 2)
Radiation Oncology (Phase 3)
Radiotherapy (Phase 1/Phase 2)
ras Proteins (Phase 3)
Rectal Diseases (Phase 2)
Rectal Neoplasms (Phase 4)
Recurrence (Phase 3)
Rhabdomyosarcoma (Phase 2)
Sarcoma (Phase 2)
Sarcoma, Ewing (Phase 2)
Self Efficacy (Phase 2)
Seminoma (Phase 2)
Sepsis (Phase 2)
Sezary Syndrome (Phase 2)
Small Cell Lung Carcinoma (Phase 2/Phase 3)
Squamous Cell Carcinoma of Head and Neck (Phase 2)
Stomach Diseases (Phase 2)
Stomach Neoplasms (Phase 4)
Survival (Phase 4)
Teratoma (Phase 3)
Testicular Neoplasms (Phase 3)
Thyroid Neoplasms (Phase 2)
Triple Negative Breast Neoplasms (Phase 1)
Urinary Bladder Neoplasms (Phase 2)
Uterine Cervical Neoplasms (Phase 3)
Uterine Neoplasms (Phase 2)
Waldenstrom Macroglobulinemia (Phase 2)
Wilms Tumor (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
